Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have newly diagnosed stage III or IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is high-grade and has a high risk of coming back.
- You had surgery to remove the main tumor (debulking) and it has been 12 weeks or less since that surgery.
- You are able to walk and take care of yourself (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within normal limits as checked by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (fluzoparib with famitinib or SHR-1701) given before surgery to shrink advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if these treatments can make tumors small enough for complete removal or improve the surgery outcome.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
This trial tests a combination of targeted therapy (surufatinib), immunotherapy (serplulimab), and standard chemotherapy as a first treatment for advanced solid tumors that have neuroendocrine features. It aims to see if this combination can shrink tumors and improve outcomes for patients with certain cancers.
This trial tests a combination of three drugs—surufatinib (a targeted therapy), camrelizumab (an immunotherapy), and a chemotherapy regimen called mFOLFOX6—as a second-line treatment for advanced pancreatic cancer. It's for people whose cancer progressed after first-line gemcitabine-based chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.